Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹616.45 - ₹1,150.00
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹101.16B
Enterprise Value₹113.97B
Total Cash (Recent Filing)₹2.27B
Total Debt (Recent Filing)₹18.44B
Price to Earnings (P/E)10.3
Beta0.82
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)21.90
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.40
Price to Sales (P/S)1.37
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.63
Revenue Forecast (FY)₹56.49B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSustained free cash flow provides durable internal funding for working capital, capex and debt reduction. Over the next 2–6 months strong FCF lowers refinancing risk, supports steady operations and gives management flexibility to invest in capacity or absorb temporary margin pressure without needing external finance.
Revenue And Margin RecoveryImproving revenue and rising gross/net margins indicate enhanced operational efficiency and pricing or mix recovery. This trend supports more predictable earnings and cash conversion going forward, bolstering the firm's ability to sustain profitability through product cycles and to fund R&D and commercialization initiatives.
In-house Manufacturing & Multi-market FootprintOwning manufacturing and a development pipeline strengthens control over costs, quality and regulatory timelines, enabling quicker scale-up and margin retention. A presence across multiple market types diversifies revenue sources and reduces exposure to any single regulatory or tender event, improving structural resilience.
Bears Say
Historical Earnings VolatilityPast swings into negative operating results signal earnings cyclicality and execution risk. Such volatility complicates forecasting and may reflect product concentration, regulatory setbacks or pricing shocks, increasing the chance that recent improvements could reverse under adverse market or competitive conditions.
Balance Sheet And Cash Management ConstraintsModerate leverage combined with uneven cash buffers limits financial flexibility for M&A, large capex or extended tender cycles. If free cash flow weakens, servicing liabilities or funding growth without costly external financing could strain operations and slow strategic investments over the medium term.
Structural Generics CompetitionOperating mainly in generics exposes the company to intense price competition, tender volatility and quick product commoditization. Over time these forces can compress margins and create revenue cyclicality, making long-term earnings and margin sustainability contingent on continual approvals, cost control and tender success.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹616.45 and its highest was ₹1150.00 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹101.16B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is May 21, 2026 which is in 22 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on Jan 30, 2026. The company reported ₹21.9 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.9.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹21.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.492%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―